Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tumor DNA-Transfected Fibroblast Vaccine in HNSCC
NCT02211027Phase 1Withdrawn
- Start
- Sep 2016
- Primary completion
- Oct 2017
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor DNA-transfected fibroblast vaccine in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Immunization Safety at 2.5 years. Planned start Sep 2016; status: withdrawn.
02
Drugs
autologous tumor DNA-transfected fibroblast vaccine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02211027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211027.